Spots Global Cancer Trial Database for Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Official Title: Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

Study ID: NCT04527666

Conditions

Gastroesophageal Varices

JAK2 Mutation

Myeloproliferative Neoplasm

Interventions

Anticoagulation Agents

Study Description

Brief Summary: Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Detailed Description: